FDA
-
-
-
-
-
-
-
Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology
-
-
-
-
-
-
-
Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026
-
-
-
-
-
-
-
CORRECTING and REPLACING: Following the signature of a financial agreement for up to €37.5 million with the EIB, Median Technologies launches an approximately €22 million capital increase to suppo
-
-
-
-
-
-
-
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
-
-
-
-
-
-
-
Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis™ Lung Cancer Screening (LCS) REALITY Data
-
-
-
-
-
-
-
Median Technologies to Participate in the 2024 ASCO Annual Meeting, May 31 - June 4, 2024, McCormick Place, Chicago, IL, USA
-
-
-
-
-
-
-
Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD
-
327,799 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

